CSL.AX - CSL Limited
| Previous close | 308.24 |
| Open | 309.56 |
| Bid | 310.45 x 13700 |
| Ask | 310.51 x 21700 |
| Day's range | 307.66 - 310.86 |
| 52-week range | 254.30 - 314.28 |
| Volume | |
| Avg. volume | 667,432 |
| Market cap | 149.776B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 46.62 |
| EPS (TTM) | 6.66 |
| Earnings date | 15 Aug 2023 - 21 Aug 2023 |
| Forward dividend & yield | 3.38 (1.10%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | 334.96 |
GlobeNewswireKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysisST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recomme
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS) from its partner Travere Therapeutics. At the end of the 108-week double-blind period, sparsentan was observed to have a 0.3 mL/min/1.73m2 per year (95% CI: -1.74, 2.41) favorable difference on eGFR total slope and a 0.9 mL/min/1.73m2 per year (95% CI: -1.27, 3.04) favorable differen
GlobeNewswireOTC Markets Group Welcomes CSL Limited to OTCQX
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX: CSL; OTCQX: CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology, has qualified to trade on the OTCQX® Best Ma
PR NewswireCSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
Global biotechnology leader CSL Behring today announced the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid). CSL Behring now offers a full range of prefilled syringe sizes to meet the individual needs of people living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Hizentra is the first and only immune globulin (Ig) available in a simple, convenient and r
Simply Wall St.Calculating The Fair Value Of CSL Limited (ASX:CSL)
Key Insights Using the 2 Stage Free Cash Flow to Equity, CSL fair value estimate is AU$295 With AU$300 share price, CSL...
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that Tavneos® has been included in the revised EULAR AAV management recommendations, as one of several important updates in the 2022 version. As part of a strategy to substantially reduce exposure to glucocorticoids, Tavneos® should be considered a therapy option in combination with rituximab or cyclophosphamide for induction of remission in patients with active granulomatosis with polyangiitis (GPA) or microscopic polyang
PR NewswireCSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts. The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory (BSL-3) in Waltham. The site will serve as CSL's central hub for current and future vaccine design.
PR NewswireThe Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The study met its primary and secondary
GlobeNewswireAmarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand. "We are excited to announce this agreement with CSL Seqirus in Austra
- PR Newswire
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL's investigational first-in-class monoclonal antibody being developed as a long-term prophylactic treatment for patients with hereditary angioedema (HAE). Results from the trial, the first to investigate targeting activated Factor XII (FXIIa) to prevent HAE attacks, showed that once-monthly subcutaneous injec
GlobeNewswireuniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time infusion ~ ~ 18-month data support the ongoing benefit of HEMGENIX® ~ ~ HEMGENIX® is approved for adults with hemophilia B in the United States, European Union and European Economic Area ~ LEXINGTON, Mass. and
PR NewswireCSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb). HEMGENIX® is the first and only gene therapy approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeate
PR NewswireBiotech Leader CSL Again Named Among America's Best Employers by Forbes
Global biotechnology leader CSL has again been recognized among America's Best Employers by Forbes and Statista.
- GlobeNewswire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~ ~ Approval marks uniQure’s second internally-developed and manufactured gene therapy to achieve licensure in the European Union ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NA
PR NewswireFirst Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors. In the ongoing clinical trial, HEMGENIX® reduced the rate of annual bleeds with a single infusion by delivering a functional
- PR Newswire
Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) in Australia has approved Tavneos® in combination with a rituximab or cyclophosphamide-based regimen for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA) – associated vasculitis (granulomatosis polyangiitis [GPA] or microscopic polyangiitis [MPA]); two main forms of AAV. Tavneos® was granted orphan drug designation by the TGA and is the first targeted therapy
ZacksWhat Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'
CSL Limited Sponsored ADR (CSLLY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
GlobeNewswireSAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today results from a project in collaboration with global biotechnology leader CSL (ASX: CSL), confirming that SAB’s DiversitAb™ platform can generate functional fully-human anti-idiotype polyclonal ant
ZacksPfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal
Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.
- GlobeNewswire
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogen
PR NewswireCSL Announces Next CEO & Managing Director
The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Dr Paul McKenzie as Chief Executive Officer (CEO) and Managing Director of CSL from 6 March 2023.
PR NewswireCSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT). The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of inf
- PR Newswire
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Global biotechnology leader CSL (ASX: CSL) today announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb) in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology (ASH) Annual Meeting. Results from the pivotal HOPE-B study, the largest gene therapy study in hemophilia B to date, demonstrated that after two years of follow-up, adults with severe or moderately severe
- Simply Wall St.
Are Robust Financials Driving The Recent Rally In CSL Limited's (ASX:CSL) Stock?
CSL (ASX:CSL) has had a great run on the share market with its stock up by a significant 6.6% over the last month...